Newsletter Tool

To view this email as a web page, click here

Today's Rundown

With pandemic restrictions lifted, FDA restarts U.S. inspections and seeks to whittle its massive backlog
UPDATED Coronavirus tracker: AHIP study finds continued 'price-gouging' for COVID tests
COVID-19 tracker: Sanofi, GSK vaccine under review in Europe; Delta variant makes up 83% of new US cases
Another medical provider group pushing healthcare employers to require COVID-19 vaccination
BioNTech makes a splash in cell therapy with purchase of factory, R&D platform from Gilead's Kite

Featured Story

With pandemic restrictions lifted, FDA restarts U.S. inspections and seeks to whittle its massive backlog

By Kevin Dunleavy

Hamstrung by the coronavirus pandemic, the FDA accumulated a huge backlog of more than 20,000 inspections. The agency now is free to starting reducing that list, at least in the United States, where it has resumed normal operations.

UPDATED Coronavirus tracker: AHIP study finds continued 'price-gouging' for COVID tests

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 tracker: Sanofi, GSK vaccine under review in Europe; Delta variant makes up 83% of new US cases

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Sanofi and GlaxoSmithKline's protein-based vaccine is now under a rolling review in Europe. The highly infectious Delta variant now makes up 83% of new U.S. infections, the head of the CDC said. And more.

Another medical provider group pushing healthcare employers to require COVID-19 vaccination

By Dave Muoio

The industry organization joins numerous professional groups backing mandatory COVID-19 vaccination policies as nationwide hospitalization rates tick upward. No small number of hospitals and health systems have already chosen to implement the requirements for a collective hundreds of thousands of healthcare staff.

BioNTech makes a splash in cell therapy with purchase of factory, R&D platform from Gilead's Kite

By Fraiser Kansteiner

Germany’s BioNTech has already risen to international prominence thanks to its Pfizer-partnered COVID-19 vaccine. Now, the mRNA specialist has lined up a deal for its first U.S. factory as it looks to make a big splash in cell therapy.

COVID-19 Tracker